Video Experimental Relacionado
Updated: Sep 9, 2025
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
19.1K
La insuficiencia del factor de coagulación XII protege contra el tromboembolismo venoso en un análisis
Amelia K Haj1,2,3, David S Paul4,5, Sean J Jurgens2,6,7
1Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Nature communications
|September 1, 2025
Resumen
Las variantes genéticas del factor de coagulación XII (F12) protegen contra el tromboembolismo venoso sin aumentar el riesgo de hemorragia. Esto sugiere que la inhibición del factor XII podría ser una estrategia terapéutica segura y efectiva.
Área de la Ciencia:
- La genética
- La hemostasis
- Farmacología
Sus antecedentes:
- El factor de coagulación XII (F12) es un objetivo potencial para la prevención de la trombosis.
- Los datos en humanos que apoyan las terapias dirigidas a F12 son limitados.
- La investigación del papel de F12 en el tromboembolismo venoso (TEV) es crucial.
Objetivo del estudio:
- Evaluar el papel de la F12 en el tromboembolismo venoso utilizando datos genéticos humanos.
- Evaluar el perfil de seguridad de las variantes F12 en relación con el sangrado y la infección.
- Explorar la base mecanicista de la deficiencia de F12 en la trombosis.
Principales métodos:
- Análisis de la variación genética en el locus F12 a través de 703,745 participantes de UK Biobank y NIH All of Us.
- Caracterización fenotípica de los portadores de la variante F12, incluido el sangrado, la infección y los niveles de F12.
- Ensayos de generación de trombina in vitro.
- Evaluación de modelos de ratones heterocigotos F12 para la protección de la TEV.
Principales resultados:
- Los portadores heterocigotos de las variantes F12 (nonsense, frameshift, sitio de empalme) mostraron protección contra el TEV.
- No se observó un aumento del riesgo de hemorragia o infección en los portadores de la variante F12.
- Los portadores de la variante F12 mostraron deficiencia cuantitativa (tipo I) de F12, y algunos mostraron deficiencia cualitativa (tipo II).
- Reducción de la generación de trombina in vitro correlacionada con los niveles de F12 en los portadores.
- Los ratones heterocigotos F12 estuvieron protegidos contra la TEV.
Conclusiones:
- La pérdida heterocigótica de la función F12 confiere protección contra la TEV.
- Este estado haploinsufficiente sugiere que la inhibición de F12 es un enfoque terapéutico potencialmente seguro y eficaz.
- La focalización en F12 justifica una mayor investigación para la prevención de la trombosis.
Videos de Conceptos Relacionados
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889
01:29Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:24Disorders of Hemostasis
1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
34
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
34
01:20Extrinsic and Intrinsic Pathways of Hemostasis
9.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.2K